Ambu A/S (OTCMKTS:AMBBY) Shares Gap Up - Here's Why

Key Points

• Ambu A/S shares experienced a price **gap up** from $15.64 to $16.31, reflecting a **4.3% increase** at the market opening on Thursday.
• The company reported a **quarterly earnings per share (EPS)** of $0.07 with revenues totaling **$229.16 million**, reflecting a **net margin of 5.93%**.
• Ambu A/S has a **market capitalization** of **$3.83 billion**, a PE ratio of **85.84**, and a strong liquidity position indicated by a current ratio of **2.90**.

Ambu A/S Unsponsored ADR (OTCMKTS:AMBBY - Get Free Report) gapped up before the market opened on Thursday . The stock had previously closed at $15.64, but opened at $16.31. Ambu A/S shares last traded at $16.31, with a volume of 500 shares.

Ambu A/S Stock Up 4.3%

The stock has a market capitalization of $3.83 billion, a PE ratio of 85.84 and a beta of 0.83. The firm's fifty day moving average is $15.33 and its 200-day moving average is $15.64. The company has a quick ratio of 1.73, a current ratio of 2.90 and a debt-to-equity ratio of 0.08.

Ambu A/S (OTCMKTS:AMBBY - Get Free Report) last announced its quarterly earnings data on Friday, August 22nd. The company reported $0.07 earnings per share (EPS) for the quarter. The company had revenue of $229.16 million during the quarter. Ambu A/S had a net margin of 5.93% and a return on equity of 6.11%.

About Ambu A/S

Ambu A/S develops, produces, and sells medical devices to hospitals, clinics, and rescue services worldwide. The company offers anaesthesia, and patient monitoring and diagnostics products. The company also offers endoscopy products, such as bronchoscopes, rhinolaryngoscopes, duodenoscopes, cystoscopes, and display units; and neurology products, including EEG and EMG electrodes, EMG guided injections, and intraoperative monitoring products.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.